Hdac inhibitor oki-179 in combination with binimetinib for the treatment of cancer
AssigneesOnKure, Inc., Array BioPharma Inc.
InventorsAnthony D. Piscopio, Patrice Anne Lee, James Winkler, Richard D. Woessner
Life of this patent
Estimating the term…
Abstract
A method of treating cancer in a subject in need thereof, wherein the method comprises administration of therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, or administration of therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to the dosing schedules described herein.
Claims20
A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-4 of the 7-day dosing cycle and binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle.
A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-5 of the 7-day dosing cycle and binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle.
A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-4 of the 7-day dosing cycle, binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle and encorafenib or a pharmaceutically acceptable salt thereof is administered once per day (QD) on days 1-7 of the 7-day dosing cycle.
A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-5 of the 7-day dosing cycle, binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle and encorafenib or a pharmaceutically acceptable salt thereof is administered once per day (QD) on days 1-7 of the 7-day dosing cycle.
A pharmaceutical combination comprising OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, and optionally encorafenib or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.